Part a. Produce the goods in-house and allow international sales managers to oversee marketing.
Advantages include:
- Complete authority over production processes.
- Simplicity in strategizing and scaling manufacturing.
- Enhanced control over human resources.
- Increased comprehension of European markets by foreign sales agents.
- Reduced exit costs in case of product failure.
Disadvantages consist of:
- Limited knowledge regarding pharmaceutical protocols in Europe.
- Risks to the brand's reputation if not correctly managed by foreign agents.
- Extra expenses in product delivery.
Part b. Produce the items in-house and establish a wholly-owned entity in Europe for marketing.
Pros encompass:
- Full oversight of manufacturing operations.
- Ease in creating strategies and ramping up production.
- Better human resource oversight.
- Protection of brand integrity since marketing is managed internally.
Cons include:
- Increased resource allocation for marketing.
- Insufficient information about pharmaceutical standards in Europe.
- Extra delivery costs.
Part c. Form a strategic partnership with a significant European pharmaceutical entity to manufacture products via a 50/50 joint venture for marketing.
Pros involve:
- Risk-sharing among the enterprises.
- No additional costs for delivery.
- Valuable insights into European regulations and marketing.
Cons involve:
- Diminished control over manufacturing.
- Share profits among partners.
- Moderate exit costs involved.
- Possible brand image damage due to the additional firm.
